表紙:下痢止め薬の世界市場 (2021-2028年)
市場調査レポート
商品コード
972305

下痢止め薬の世界市場 (2021-2028年)

Global Anti-Diarrheal Drugs Market - 2021-2028

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
下痢止め薬の世界市場 (2021-2028年)
出版日: 2021年07月09日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の下痢止め薬/止しゃく薬市場の成長は、下痢の高い有病率と下痢止め薬の高い採用率によって推進されています。世界の下痢止め薬市場をけん引する要因は、下痢止め薬に対する認識の高まり、医療施設の改善に対する政府イニシアチブの増加、および下痢の有病率の上昇です。

しかし、研究開発に対する高額な投資コストは、市場の成長を妨げる可能性があります。加えて、胃痛、嘔吐、便秘、吐き気、食欲減退といった重度の副作用は、市場成長を抑制しています。更に、新興諸国では依然として伝統的・家庭療法が一般的であり、このことも下痢止め薬市場の成長を抑制しています。

当レポートでは、世界の下痢止め薬/止しゃく薬市場について調査し、市場の概要、各セグメントおよび地域別の市場分析と予測、競合情勢の分析、主要企業のプロファイルなどを提供しています。

目次

第1章 世界の下痢止め薬市場:調査範囲・手法

  • 調査手法
  • 調査目的・調査範囲

第2章 世界の下痢止め薬市場:市場定義・概要

第3章 世界の下痢止め薬市場:エグゼクティブサマリー

  • 市場内訳:タイプ別
  • 市場内訳:医薬品クラス別
  • 市場内訳:流通チャネル別
  • 市場内訳:地域別

第4章 世界の下痢止め薬市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の下痢止め薬市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 医療費償還分析
  • アンメットニーズ

第6章 世界の下痢止め薬市場:COVID-19分析

  • 市場におけるCovid-19の分析
    • COVID-19:以前の市場シナリオの前
    • COVID-19:現在の市場シナリオ
    • COVID-19:以降または将来のシナリオ
  • Covid-19における価格のダイナミクス
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の下痢止め薬市場:製品タイプ別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):製品タイプ別
    • 市場魅力指数:製品タイプ別
  • OTC医薬品
  • 処方薬
  • 抗生物質
  • その他

第8章 世界の下痢止め薬市場:医薬品クラス別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):医薬品クラス別
    • 市場魅力指数:医薬品クラス別
  • 粘膜保護剤
  • 運動性修飾薬
  • 粘膜吸収剤

第9章 世界の下痢止め薬市場:流通チャネル別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):流通チャネル別
    • 市場魅力指数:流通チャネル別
  • 病院薬局
  • 薬局
  • その他

第10章 世界の下痢止め薬:地域別

  • イントロダクション
    • 市場規模分析・前年比成長分析(%):地域別
    • 市場魅力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • 市場規模分析・前年比成長分析(%):タイプ別
    • 市場規模分析・前年比成長分析(%):医薬品クラス別
    • 市場規模分析・前年比成長分析(%):流通チャネル別
    • 市場規模分析・前年比成長分析(%):国別
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第11章 世界の下痢止め薬:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 世界の下痢止め薬:企業プロファイル

  • Actelion
  • Lupin
  • GSK
  • Glenmark Pharmaceuticals
  • Perrigo
  • Pfizer, Inc.
  • Johnson & Johnsons,
  • Novartis
  • Proctor & Gamble Pharmaceuticals
  • Bayer

第13章 重要考察

第14章 DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH2840

Market Overview

The Global Anti-Diarrheal Drugs Market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Anti-diarrheal drugs refer to a class of drugs that are used to treat diarrhea. Diarrhea is a bowel movement (stool) that is loose and watery. It is one of the common, non-serious conditions and can be treated with over-the-counter medicines.

Market Dynamics

The global anti-diarrheal drugs market growth is driven by the high prevalence of diarrhea cases and high adoption rate for anti-diarrheal drugs. Rising government initiatives for improvement in healthcare facilities is also driving the growth of the market in the forecast period.

Introduction of anti diarrheal drugs for HIV/AIDS, is expected to drive the growth in the forecast period

Introduction of anti diarrheal drugs for HIV/AIDS such as Fulyzaq (crofelemer) by Glenmark Pharmaceuticals are expected to drive the growth of the market in the near future. Anti diarrheal help in controlling severe symptoms however are contra-indicated in patients with fever or bloody diarrhea. Various side effects associated with anti-diarrheal drugs include mouth dryness, dizziness and drowsiness.

For instance, Aemcolo, an oral antibacterial rifamycin, was approved by the FDA in November 2018 to treat traveler's diarrhea caused by E.coli. Clinical studies have revealed that rifamycin has greater efficiency in reducing the symptoms of diarrhea symptoms compared to placebo.

Increase in the number of people suffering with diarrhea is rising expected to drive the market growth

The number of people suffering with diarrhea is rising, and this is one of the driving factors for the market. According to the WHO, diarrhea kills around 525, 000 children under five years of age every year. As per the CDC, diarrheal diseases account for one in nine child deaths worldwide, making diarrhea the second leading cause of death among children under the age of five years.

In addition, according to the World Tourism Organization (UNWTO), in 2019, around 1.5 billion international tourist arrivals were recorded, which was a 4% rise from 2018. The prevalence of diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia. The travel destination is the most significant risk factor for diarrhea. Hence, owing to these factors, the market is likely to witness significant growth during the forecast period.

High investment costs in R&D is likely to hinder the market growth

However, severe side effects of drugs that include stomach pain, vomiting, constipation, nausea and decrease in appetite will restricts the growth of this market. In addition, traditional and home remedies are still popular in emerging countries; this restrains the anti-diarrheal drugs market from growing.

COVID-19 Impact Analysis

Diarrhea commonly occurs in people with COVID-19. The study publised in the American Journal of Gastroenterology examined 206 patients with a mild case of COVID-19. They found 48 people had only digestive symptoms and another 69 had both digestive and respiratory symptoms. Of the combined total of 117 people with gastric distress, 19.4 percent experienced diarrhea as their first symptom. An increasing number of diarrhea cases is reported. These factors will drive the growth of the market.

Segment Analysis

OTC drugs segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

OTC drugs are medications that are safe and effective for use by the general public without seeking treatment by a health professional. OTC drugs usually work for sudden or short-term diarrhea. It include pain relievers like acetaminophen (Tylenol) and ibuprofen (Advil, Motrin), cough suppressants such as dextromethorphan (Robitussin) and antihistamines like loratadine (Claritin 24H). These drugs are usually located on shelves in pharmacies, grocery stores, and even in gas stations. OTC medicines treat a variety symptoms due to illness including pain, coughs and colds, diarrhea, heartburn, constipation, acne, and others.

OTC anti-diarrheal medicine doesn't usually cause problems. But like other drugs, there's always a chance of unwanted side effects. Some are mild, while others are more serious.

The hospital pharmacy are expected to dominate the Anti-Diarrheal drugs market during the forecast period

The hospital pharmacies held the largest share in the global anti-diarrheal drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global anti-diarrheal drugs market

North America region is dominating the global anti-diarrheal drugs market accounted for the largest market share in 2020. The presence of sophisticated healthcare infrastructure and high awareness among end-users such as clinicians and healthcare professionals are estimated to be the key growth drivers. Moreover, high purchasing power for expensive drugs and the presence of favorable reimbursement policies are anticipated to further fuel the regional market during the forecast period. Acute diarrhea is one of the most commonly reported illnesses in the United States. According to the WHO, diarrhea is the second leading cause of death, especially in children less than 5 years of age. Prevention of the diarrheal disease can be achieved by drinking of safe water coupled with adequate hygiene and sanitation. These factors are driving the market growth in the region.

Competitive Landscape

The anti-diarrheal drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Actelion, Lupin, GSK, Glenmark Pharmaceuticals, Perrigo, Pfizer, Inc. Johnson & Johnsons, Novartis, Proctor & Gamble Pharmaceuticals among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anti-diarrheal drugs market globally.

Glenmark Pharmaceuticals Limited

Overview: Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Product Portfolio: The Company's portfolio comprised 164 products including of API business, an independent subsidiary called Glenmark Life Sciences, Glenmark Pharmaceuticals is focused in the areas of respiratory and dermatology.

Why Purchase the Report?

  • Visualize the composition of the anti-diarrheal drugs market segmentation by type, drug class, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in anti-diarrheal drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of anti-diarrheal drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global anti-diarrheal drugs market report would provide an access to an approx. 61 market data table, 55 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Anti-Diarrheal Drugs Market - By Type

  • OTC Drugs
  • Prescription Drugs
  • Antibiotics
  • Other

Global Anti-Diarrheal Drugs Market - By Drug Class

  • Mucosal Protectants
  • Motility Modifying Drugs
  • Mucosal Absorbents

Global Anti-Diarrheal Drugs Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores,
  • Others

Global Anti-Diarrheal Drugs Market - By Region

  • North America
  • South America
  • Europe

Table of Contents

1. Global Anti-Diarrheal Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Anti-Diarrheal Drugs Market - Market Definition and Overview

3. Global Anti-Diarrheal Drugs Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Drug Class
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Anti-Diarrheal Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Introduction of anti-diarrheal drugs for HIV/AIDS
      • 4.1.1.2. Increase in the number of people suffering with diarrhea is rising
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Anti-Diarrheal Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Anti-Diarrheal Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Anti-Diarrheal Drugs Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. OTC Drugs *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Prescription Drugs
  • 7.4. Antibiotics
  • 7.5. Other

8. Global Anti-Diarrheal Drugs Market - By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Mucosal Protectants *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Motility Modifying Drugs
  • 8.4. Mucosal Absorbents

9. Global Anti-Diarrheal Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Anti-Diarrheal Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6.
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Anti-Diarrheal Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Anti-Diarrheal Drugs Market- Company Profiles

  • 12.1. Actelion*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Lupin
  • 12.3. GSK
  • 12.4. Glenmark Pharmaceuticals
  • 12.5. Perrigo
  • 12.6. Pfizer, Inc.
  • 12.7. Johnson & Johnsons,
  • 12.8. Novartis
  • 12.9. Proctor & Gamble Pharmaceuticals
  • 12.10. Bayer

LIST NOT EXHAUSTIVE

13. Global Anti-Diarrheal Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us